JOURNEY MEDICAL CORPORATION

Analyst Reco. Journey Medical Corporation

Equities

DERM

US48115J1097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
4.7 ^USD	+0.43%		+20.51%	-18.40%

May. 13	Transcript : Journey Medical Corporation, Q1 2024 Earnings Call, May 13, 2024
May. 13	Journey Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alliance Global Partners Starts Coverage on Journey Medical With Buy Rating, $8.50 Price Target	Feb. 16	MT
B. Riley Lifts Journey Medical's PT to $8 From $6 After US FDA Gives Green Light for DFD-29's Year-End 2023 Filing, Keeps Buy Rating	Dec. 07	MT
B. Riley Raises Journey Medical's PT to $6 From $3 On 'Impressive' Results From DFD-29 Study in Moderate to Severe Papulopustular Rosacea, Keeps Buy Rating	23-07-12	MT
B. Riley Cuts Journey Medical's Price Target to $3 From $6, Keeps Buy Rating	23-05-23	MT
B. Riley Lowers Journey Medical's Price Target to $6 From $10 After Q3 Topline Miss on Generic Competition, Keeps Buy Rating	22-11-14	MT
B. Riley Lowers Journey Medical's Price Target to $10 from $14, Keeps Buy Rating	22-05-11	MT
Cantor Fitzgerald Reinstates Journey Medical at Overweight with $9 Price Target	22-02-25	MT
Roth Capital Starts Journey Medical at Buy With $15 Price Target	21-12-16	MT
B. Riley Starts Journey Medical at Buy with $14 PT, Says Well-Positioned for Revenue, Earnings Growth	21-12-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer